West Pharmaceutical Services, Inc. (NYSE:WST) shares surged Thursday after the company's first-quarter 2026 earnings surpassed analyst estimates.

The injectable solutions company reported adjusted earnings of $2.13 per share, beating the consensus of $1.68.

Net sales of $844.90 million increased 21% year over year, with organic growth was 15.3%, beating the consensus of $779.97 million.

Proprietary Products sales of $694.3 million grew by 23.3% and increased 17.5% on an organic basis.

HVP components, which represents 48% of the company’s total net sales, continue to be the key growth driver.

Read Also:

Union Pacific Delivers Earnings Beat, Shares Move Higher On Strong Quarterly Results

Oral GLP-1 Trend Expands Market Opportunity

HVP components grew 23% on an organic basis, led by strong performance in both GLP-1 and GLP n